Target Immune Profiling MIODx focuses on profiling an individual’s adaptive immune system over time using the ClonoMap platform, presenting a potential opportunity to offer complementary bioinformatics services, data integration, and longitudinal analytics partnerships to pharma and biotech clients seeking prognostic tools.

Cloud Collaboration Recent deployment of ClonoMap Immune Profiler on DNAnexus Titan enables cloud-based project sharing and secure data access, suggesting a sales angle for cloud-enabled workflow integration, data governance solutions, and enterprise-ready collaboration features.

Early Stage Scale With a small team and revenue under one million dollars, MIODx represents a niche, early-stage partner ideal for lightweight pilot programs, prototyping collaborations, and grant-funded initiatives with faster decision cycles.

Funding Signal Funding of 1.5 million indicates recent investor interest and potential runway for partnerships; approaching for joint development, co-commercialization, or grant-backed studies could align with investor and portfolio company goals.

Competitive Landscape Positioned among genomics and diagnostic players with comparable peers, MIODx offers a targeted integration point for assay development, T cell diversity analytics, and clinical outcome studies that could complement larger platforms in Invitae, Guardant, Foundation Medicine, and peers.